Intellectual Property Portfolio
Sangui Bio has a strong and broad patent portfolio, that is managed by the leading US legal and patent firm – Jones Day. The portfolio comprises two PCT-stage patent applications and one provisional patent application based on more recent discoveries in red blood cell biology. The first PCT application published in April 2017.
Sangui Bio’s intellectual property portfolio covers applications across:
Biomarker research – multiplex assays such as Luminex
Clinical diagnostics – including clinical trial pre-screening
Monitoring treatment effects
Modulating red blood cell function to alter the immune response
Blood preparation and profiling (WO2017059477A1)
Diagnostic focus. The first patent application was filed in October 2015. This relates to methods of producing protein profiles from blood comprising red blood cell-enriched samples. The patent application details proteins that Sangui Bio has detected on RBCs, where no previous literature has reported these associations.
Therapeutic methods using erythrocytes (WO2017106899A2)
Therapeutic focus. The second patent application was filed in December 2015. This relates to methods for altering the protein profile and function of RBCs and therapeutic uses of these ‘primed’ cells. The functionally altered RBCs may be used as therapeutics in their own right or as adjuncts to other therapeutics. Additionally, primed RBCs may be used to alter the growth and function of other immune cells, potentially in the production of cells for immuno-therapy.
Blood profiling with protease inhibitors
Disease focus. The third patent application was filed in December 2016. This relates to methods for detecting and quantifying altered levels of proteins, such as cytokines, in RBCs and their components, isolated from disease samples. The research also identified that treatment of RBCs with protease inhibitors (PI) enabled otherwise undetected differences between normal and disease RBCs to be quantified. This knowledge contributes to the potential development of diagnostic technologies which are currently unavailable.